Aura Biosciences, Inc. Increase (Decrease) in Accounts Payable
Aura Biosciences, Inc. (AURA) reported Increase (Decrease) in Accounts Payable of $698.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- Aura Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$326.00K.
- Aura Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.02M.
- Aura Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$430.00K, a 238.71% decline year-over-year.
- Aura Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $602.00K, a 12.63% decline year-over-year.
- Aura Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$846.00K, a 275.52% decline from fiscal 2024.
- Aura Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2024 was $482.00K.
- Aura Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$1.04M, a 405.88% decline from fiscal 2022.
- Aura Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2022 was $340.00K, a 67.74% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$326.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $698.00K 10-Q · filed 2026-08-11 | $268.00K derived: sum of 3 quarters · filed 2026-08-11 | $870.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $1.02M 10-Q · filed 2026-05-11 | $594.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.20M derived: sum of 3 quarters · filed 2026-05-11 | $476.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$430.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $172.00K derived: sum of 2 quarters · filed 2026-03-30 | -$548.00K derived: sum of 3 quarters · filed 2026-08-11 | -$846.00K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $602.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$118.00K derived: sum of 2 quarters · filed 2026-08-11 | -$416.00K 10-Q · filed 2025-11-13 | -$106.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$720.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.02M 10-Q · filed 2026-08-11 | -$708.00K derived: sum of 3 quarters · filed 2026-08-11 | -$19.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$298.00K 10-Q · filed 2026-05-11 | $12.00K derived: sum of 2 quarters · filed 2026-05-11 | $701.00K derived: sum of 3 quarters · filed 2026-05-11 | $161.00K derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $310.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $999.00K derived: sum of 2 quarters · filed 2026-03-30 | $459.00K derived: sum of 3 quarters · filed 2026-03-30 | $482.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $689.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $149.00K derived: sum of 2 quarters · filed 2025-11-13 | $172.00K 10-Q · filed 2025-11-13 | $629.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$540.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$517.00K 10-Q · filed 2025-08-13 | -$60.00K derived: sum of 3 quarters · filed 2025-08-13 | $825.00K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $23.00K 10-Q · filed 2025-05-15 | $480.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.36M derived: sum of 3 quarters · filed 2025-05-15 | $864.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $457.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.34M derived: sum of 2 quarters · filed 2025-03-24 | $841.00K derived: sum of 3 quarters · filed 2025-03-24 | -$1.04M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $885.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $384.00K derived: sum of 2 quarters · filed 2024-11-12 | -$1.50M 10-Q · filed 2024-11-12 | -$479.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$501.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.38M 10-Q · filed 2024-08-08 | -$1.36M derived: sum of 3 quarters · filed 2024-08-08 | -$527.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$1.88M 10-Q · filed 2024-05-09 | -$863.00K derived: sum of 2 quarters · filed 2024-05-09 | -$26.00K derived: sum of 3 quarters · filed 2024-05-09 | -$784.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $1.85M derived: sum of 2 quarters · filed 2024-03-27 | $1.10M derived: sum of 3 quarters · filed 2024-03-27 | $340.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $837.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $79.00K derived: sum of 2 quarters · filed 2023-11-09 | -$678.00K 10-Q · filed 2023-11-09 | -$515.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$758.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.51M 10-Q · filed 2023-08-09 | -$1.35M derived: sum of 3 quarters · filed 2023-08-09 | -$2.07M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$757.00K 10-Q · filed 2023-05-11 | -$756.00K 10-Q · filed 2022-05-12 | -$594.00K derived: sum of 2 quarters · filed 2023-05-11 | -$1.31M derived: sum of 3 quarters · filed 2023-05-11 | -$403.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$558.00K derived: sum of 2 quarters · filed 2023-03-15 | $354.00K derived: sum of 3 quarters · filed 2023-03-15 | $1.05M 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$721.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $191.00K derived: sum of 2 quarters · filed 2022-11-10 | $891.00K 10-Q · filed 2022-11-10 | $1.01M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $912.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.61M 10-Q · filed 2022-08-11 | $1.73M derived: sum of 3 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $700.00K 10-Q · filed 2022-05-12 | $816.00K derived: sum of 2 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$1.72M 10-K · filed 2022-03-23 | |||
| 2020-09-30 | -$1.84M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |